天坛生物(600161) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was CNY 1,231,987,432.92, a decrease of 7.44% compared to the same period last year[1] - Net profit attributable to shareholders for Q3 2024 was CNY 325,631,579.67, an increase of 1.57% year-on-year[1] - The basic earnings per share for Q3 2024 was CNY 0.16, reflecting a year-on-year increase of 1.57%[1] - The net profit excluding non-recurring gains and losses for Q3 2024 was CNY 320,449,185.78, a slight increase of 0.04% year-on-year[1] - Total operating revenue for the first three quarters of 2024 reached CNY 4,073,361,821.56, a slight increase from CNY 4,022,002,501.05 in the same period of 2023, representing a growth of approximately 1.3%[12] - Net profit for the first three quarters of 2024 was CNY 1,427,390,948.39, compared to CNY 1,207,616,323.66 in 2023, reflecting an increase of approximately 18.2%[13] - The total comprehensive income for Q3 2024 reached CNY 1,446,486,664.53, compared to CNY 1,207,616,323.66 in Q3 2023, indicating an increase of about 19.8%[14] - The net profit attributable to shareholders of the parent company for Q3 2024 was CNY 1,051,719,466.85, an increase from CNY 887,400,407.26 in Q3 2023, representing a growth of approximately 18.5%[14] Cash Flow and Liquidity - The net cash flow from operating activities for Q3 2024 decreased by 91.39% to CNY 92,011,405.09 compared to the previous quarter[1] - The net cash flow from operating activities for the year-to-date period decreased by 44.52% to CNY 1,298,751,779.50 compared to the same period last year[4] - Cash flow from operating activities for the first three quarters of 2024 was CNY 1,298,751,779.50, down from CNY 2,341,139,295.54 in the same period of 2023, a decrease of about 44.5%[15] - The company reported a decrease in cash inflow from sales of goods and services, totaling CNY 4,018,855,673.47 for the first three quarters of 2024, down from CNY 4,974,086,029.35 in 2023, a decline of about 19.2%[15] - The company's cash and cash equivalents as of September 30, 2024, amount to approximately RMB 4.80 billion, an increase from RMB 4.55 billion at the end of 2023[9] - The cash and cash equivalents at the end of Q3 2024 amounted to CNY 3,540,499,295.77, compared to CNY 3,348,181,272.87 at the end of Q3 2023, showing an increase of about 5.7%[16] - The company experienced a net decrease in cash and cash equivalents of -1,407,031,634.47 RMB, contrasting with an increase of 1,399,409,326.02 RMB in the same period last year[24] Assets and Liabilities - Total assets as of the end of the reporting period were CNY 15,553,620,689.84, representing a year-on-year increase of 9.62%[2] - Total assets as of the end of Q3 2024 amounted to CNY 15,553,620,689.84, up from CNY 14,188,056,936.91 at the end of Q3 2023, representing an increase of approximately 9.6%[11] - Total liabilities increased to CNY 1,705,021,143.31 in Q3 2024 from CNY 1,433,686,959.69 in Q3 2023, indicating a growth of about 18.9%[11] - The company's total equity reached CNY 13,848,599,546.53 in Q3 2024, compared to CNY 12,754,369,977.22 in Q3 2023, reflecting an increase of approximately 8.6%[11] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 48,667, with the largest shareholder, China Biotechnology Co., Ltd., holding 902,500,488 shares, accounting for 45.64%[5] - There are no significant changes in the shareholding structure or major shareholder actions reported during the period[6] Research and Development - The company has ongoing research and development efforts, with development expenditures amounting to RMB 382.98 million, up from RMB 363.59 million[9] - Research and development expenses increased to CNY 98,702,282.76 in 2024 from CNY 58,350,420.20 in 2023, marking a rise of about 69.2%[13] Operational Challenges - The company’s operational cash flow remains negative, indicating ongoing challenges in generating positive cash flow from core business activities[23] - The company has not disclosed any new strategies or mergers and acquisitions in this reporting period[8] - The company has not adopted the new accounting standards for the current year, which may impact future financial reporting[25]